Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.

Exposure to potentially dangerous drug-drug interactions involving antipsychotics.

Guo JJ, Wu J, Kelton CM, Jing Y, Fan H, Keck PE, Patel NC.

Psychiatr Serv. 2012 Nov;63(11):1080-8. doi: 10.1176/appi.ps.201100443.

PMID:
22910806
2.

Geographic and clinical variation in clozapine use in the United States.

Stroup TS, Gerhard T, Crystal S, Huang C, Olfson M.

Psychiatr Serv. 2014 Feb 1;65(2):186-92. doi: 10.1176/appi.ps.201300180.

PMID:
24233347
3.

Ethnicity and prescription patterns for haloperidol, risperidone, and olanzapine.

Opolka JL, Rascati KL, Brown CM, Gibson PJ.

Psychiatr Serv. 2004 Feb;55(2):151-6.

PMID:
14762239
4.

Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.

Lambert BL, Chou CH, Chang KY, Tafesse E, Carson W.

Pharmacoepidemiol Drug Saf. 2005 Jun;14(6):417-25.

PMID:
15786516
5.
6.

Variation in long-term antipsychotic polypharmacy and high-dose prescribing across physicians and hospitals.

Latimer EA, Naidu A, Moodie EE, Clark RE, Malla AK, Tamblyn R, Wynant W.

Psychiatr Serv. 2014 Oct;65(10):1210-7. doi: 10.1176/appi.ps.201300217.

PMID:
24981557
7.

A Non-Interventional Naturalistic Study of the Prescription Patterns of Antipsychotics in Patients with Schizophrenia from the Spanish Province of Tarragona.

Gaviria AM, Franco JG, Aguado V, Rico G, Labad J, de Pablo J, Vilella E.

PLoS One. 2015 Oct 1;10(10):e0139403. doi: 10.1371/journal.pone.0139403. eCollection 2015.

8.

Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000.

Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC.

J Clin Psychiatry. 2004 Oct;65(10):1377-88.

PMID:
15491242
9.

Prescribing of antipsychotics in UK primary care: a cohort study.

Marston L, Nazareth I, Petersen I, Walters K, Osborn DP.

BMJ Open. 2014 Dec 18;4(12):e006135. doi: 10.1136/bmjopen-2014-006135.

10.

Diagnoses associated with use of atypical antipsychotics in a commercial health plan: a claims database analysis.

Citrome L, Kalsekar I, Guo Z, Laubmeier K, Hebden T.

Clin Ther. 2013 Dec;35(12):1867-75. doi: 10.1016/j.clinthera.2013.09.006. Epub 2013 Oct 8.

11.

Association between antipsychotic treatment and hyperlipidemia among California Medicaid patients with schizophrenia.

Lambert BL, Chang KY, Tafesse E, Carson W.

J Clin Psychopharmacol. 2005 Feb;25(1):12-8.

PMID:
15643095
12.

Cost of antipsychotic polypharmacy in the treatment of schizophrenia.

Zhu B, Ascher-Svanum H, Faries DE, Correll CU, Kane JM.

BMC Psychiatry. 2008 Apr 4;8:19. doi: 10.1186/1471-244X-8-19.

13.

State and demographic variation in use of depot antipsychotics by Medicaid beneficiaries with schizophrenia.

Brown JD, Barrett A, Caffery E, Hourihan K, Ireys HT.

Psychiatr Serv. 2014 Jan 1;65(1):121-4. doi: 10.1176/appi.ps.201300001.

PMID:
24382765
14.

Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.

Morrato EH, Dodd S, Oderda G, Haxby DG, Allen R, Valuck RJ.

Clin Ther. 2007 Jan;29(1):183-95.

PMID:
17379060
15.

Outcomes of medicaid beneficiaries with schizophrenia receiving clozapine only or antipsychotic combinations.

Velligan DI, Carroll C, Lage MJ, Fairman K.

Psychiatr Serv. 2015 Feb 1;66(2):127-33. doi: 10.1176/appi.ps.201300085. Epub 2014 Oct 15.

PMID:
25321616
16.

Risk of arrest in persons with schizophrenia and bipolar disorder in a Florida Medicaid program: the role of atypical antipsychotics, conventional neuroleptics, and routine outpatient behavioral health services.

Van Dorn RA, Andel R, Boaz TL, Desmarais SL, Chandler K, Becker MA, Howe A.

J Clin Psychiatry. 2011 Apr;72(4):502-8. doi: 10.4088/JCP.10m06618.

PMID:
21527125
17.

Patient, Physician and Organizational Influences on Variation in Antipsychotic Prescribing Behavior.

Tang Y, Chang CC, Lave JR, Gellad WF, Huskamp HA, Donohue JM.

J Ment Health Policy Econ. 2016 Mar;19(1):45-59.

18.

Hyperlipidemia following treatment with antipsychotic medications.

Olfson M, Marcus SC, Corey-Lisle P, Tuomari AV, Hines P, L'Italien GJ.

Am J Psychiatry. 2006 Oct;163(10):1821-5.

PMID:
17012695
19.

Patterns of antipsychotic prescription to patients with schizophrenia in Korea: results from the health insurance review & assessment service-national patient sample.

Park SC, Lee MS, Kang SG, Lee SH.

J Korean Med Sci. 2014 May;29(5):719-28. doi: 10.3346/jkms.2014.29.5.719. Epub 2014 Apr 25.

20.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
Items per page

Supplemental Content

Write to the Help Desk